{"name":"Hangzhou Zede Pharma-Tech Co., Ltd.","slug":"hangzhou-zede-pharma-tech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CN128 Tablets","genericName":"CN128 Tablets","slug":"cn128-tablets","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CN128 Tablets","genericName":"CN128 Tablets","slug":"cn128-tablets","phase":"phase_2","mechanism":"CN128 Tablets' mechanism is currently unknown.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxQLUF4dlhwYklLWW0zd1hkcGtoVVdzWjhQdjdQYzRqWWljS21Hc3JXeWw0ZTBleTlENGZVRi1nLWV2R2ZTWUoyOHBCZFk0dy1Sb3pBNy1WMEdtbW9ZZWpfLVl4djZfZVdEM0N3anJON1NheFh6RzdFLTNlQmdONW5vV2hEUlFSU214LU9peHZibG4xU2FrUk9xajhlcE1lTEQtQXVVZ2U1YUpOejMwMWt3Z2NSd3FXZmlpN05lQkdFRHZZVUN0UXd3S0tPRExFeHBySlZtdndzeGF3N3VlZnBlVXFPdDJnZ3BXRWlacXZxMA?oc=5","date":"2025-03-18","type":"regulatory","source":"PR Newswire UK","summary":"EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight - PR Newswire UK","headline":"EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}